

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL


OMB Number: 3235-0076

Expires: August 31, 2015

Estimated Average burden hours per response: 4.0

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	<b>▼</b> None	Entity Type
0000910267			© Corporation
Name of Issuer			C Limited Partnership
TITAN PHARMACEUTICALS INC			C Limited Liability Company
Jurisdiction of Incorporation/Organization	•		C General Partnership
DELAWARE			C Business Trust
Year of Incorporation/Organization	1		C Other
Over Five Years Ago			
C Within Last Five Years (Specify Year)			
C Yet to Be Formed			

2. Principal Plac	e of Business and Contact Information
Name of Issuer	
TITAN PHARMACEUTI	CALS INC
Street Address 1	Street Address 2
400 OYSTER POINT BL	D SUITE 505
City	State/Province/Country ZIP/Postal Code Phone No. of Issuer
SAN FRANCISCO	CALIFORNIA 94080 6502444990



Last Name		First Name		Middle Name	
Akers		Joseph		A.	
Street Address 1			Street Address 2		
400 OYSTER POINT	BLVD		SUITE 505		
City		State/Province/Country		ZIP/Postal Code	
SAN FRANCISCO		CALIFORNIA		94080	
Relationship:	Executi	ve Officer	Director	Promoter	
Clarification of Response	(if Necessary)	)			
				_	
Last Name		First Name		Middle Name	
McFarlane		M.		David	
Street Address 1	Street Address 1 Street Address 2				
400 OYSTER POINT	BLVD		SUITE 505		
City State/Prov		State/Province/C	Country	ZIP/Postal Code	
SAN FRANCISCO		CALIFORNIA		94080	
Relationship:	Executi	ve Officer	Director	Promoter	
Clarification of Response	(if Necessary)	)			
-					
Last Name		First Name		Middle Name	
Last Name McNab, Jr.		First Name		Middle Name	
			Street Address 2	11	
McNab, Jr.	BLVD		Street Address 2 SUITE 505	11	
McNab, Jr. Street Address 1	BLVD		SUITE 505	11	
McNab, Jr.  Street Address 1  400 OYSTER POINT	BLVD	James	SUITE 505	[R.	
McNab, Jr.  Street Address 1  400 OYSTER POINT  City	BLVD	James  State/Province/C	SUITE 505	ZIP/Postal Code	
McNab, Jr.  Street Address 1  400 OYSTER POINT  City		James  State/Province/C	SUITE 505	ZIP/Postal Code	

## 4. Industry Group

C Agriculture  Banking & Financial Services  C Commercial Banking  C Insurance C Investing C Investment Banking C Pooled Investment Fund Other Banking & Financial C Services  C Business Services  Energy C Coal Mining C Electric Utilities C Energy Conservation C Environmental Services C Oil & Gas C Other Energy	Health Care  Biotechnology  Health Insurance  Hospitals & Physicians  Pharmaceuticals  Other Health Care   Manufacturing  Real Estate  Commercial  Construction  REITS & Finance  Residential  Other Real Estate	Retailing Restaurants Technology Computers C Telecommunications C Other Technology  Travel C Airlines & Airports C Lodging & Conventions C Tourism & Travel Services C Other Travel C Other
5 Januar Ci-a		
5. Issuer Size		
Revenue Range	Aggregate Net Asset	Value Range
C No Revenues	C No Aggregate	e Net Asset Value
C \$1 - \$1,000,000	\$1 - \$5,000,00	00
\$1,000,001 - \$5,000,000	\$5,000,001 - 5	\$25,000,000
C \$5,000,001 - \$25,000,000	C \$25,000,001 -	\$50,000,000
C \$25,000,001 - \$100,000,000	C \$50,000,001 -	\$100,000,000
Over \$100,000,000	Over \$100,00	00,000
© Decline to Disclose	C Decline to Di	sclose
C Not Applicable	C Not Applicab	ole
6. Federal Exemption(s) a apply)  Rule 504(b)(1) (not (i), (ii) or (ii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii)	nd Exclusion(s) Clain  Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Sec	
7. Type of Filing		
New Notice Date of First Sale	2021-01-20	First Sale Yet to Occur
Amendment	1021 01 20	nst suc ret to occur
8. Duration of Offering		
Does the Issuer intend this offering to last m	ore than one year?	Yes © No
9. Type(s) of Securities O	ffered (select all that :	apply)
- Pooled Investment Fund -		appry)
Interests Interests	quity	
	lebt	
	Option, Warrant or Other Right to ecquire Another Security	

굣	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security  Other (describe)
10	). Business Combination Transaction
	us offering being made in connection with a business combination Section, such as a merger, acquisition or exchange offer?
Claı	rification of Response (if Necessary)
	. Minimum Investment
inve	imum investment accepted from any outside stor
12	. Sales Compensation
Rec	ipient Recipient CRD Number None
(As	sociated) Broker or Dealer None (Associated) Broker or Dealer CRD Number
Str	reet Address 1 Street Address 2
City	y State/Province/Country ZIP/Postal Code
Stat	e(s) of Solicitation
40	Official and Color Amounts
IJ	3. Offering and Sales Amounts
Tota	al Offering Amount \$ 9673750 USD   Indefinite
Tota	al Amount Sold \$ 9673750 USD
Tota Sold	al Remaining to be \$ 0 USD ☐ Indefinite
Claı	rification of Response (if Necessary)
14	. Investors
	Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,  Number of such non-accredited investors who already have invested in the offering
	Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15	i. Sales Commissions & Finders' Fees Expenses
Pro	vide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an enditure is not known, provide an estimate and check the box next to the amount.
слр	Sales Commissions \$ 0 USD Estimate
	Finders' Fees \$ 677162 USD Estimate

Clarification of Response (if Necessary)
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$ USD Estimate
Clarification of Response (if Necessary)

## Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

## **Terms of Submission**

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
  described and undertaking to furnish them, upon written request, the information furnished to
  offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
TITAN PHARMACEUTIC INC	ALS /s/ Kate Beebe DeVarney, Ph.D	Kate Beebe DeVarney, Ph.D.	President and COO	2021-01-20